Summary
Gilead Sciences, Inc. (GILD) reported third quarter and year-to-date results for 2018. Total revenues for the third quarter of 2018 were $5.6 billion, a decrease from $6.5 billion in the prior year's quarter, driven by a 15% decline in product sales. For the nine-month period, total revenues decreased by 19% to $16.3 billion, also primarily due to lower product sales. This decline is largely attributable to a significant decrease in Hepatitis C (HCV) product sales, which fell 59% year-over-year in the third quarter and 61% year-over-year for the nine-month period. The company attributes this to increased competition. On a positive note, HIV product sales showed resilience, increasing by 12% in the third quarter and 10% for the nine-month period, driven by strong uptake of newer treatments like Descovy, Genvoya, Odefsey, and the newly launched Biktarvy. Despite the revenue challenges in HCV, Gilead maintained a strong financial position with $30.8 billion in cash, cash equivalents, and marketable securities as of September 30, 2018. The company generated $6.1 billion in operating cash flow for the nine months ended September 30, 2018, but used significant cash for debt repayments ($1.8 billion senior unsecured notes, $4.5 billion term loans) and stock repurchases ($1.9 billion), leading to a net decrease in cash. Research and development expenses increased notably by 19% for both periods, driven by costs associated with the Kite Pharma acquisition, while Selling, General, and Administrative expenses also saw increases. The company continues to invest in its pipeline and integrate the Kite acquisition, positioning for future growth in oncology and other therapeutic areas.
Financial Highlights
57 data points| Revenue | $5.60B |
| Cost of Revenue | $1.09B |
| Gross Profit | $4.37B |
| R&D Expenses | $939.00M |
| SG&A Expenses | $948.00M |
| Operating Expenses | $2.97B |
| Operating Income | $2.62B |
| Interest Expense | $264.00M |
| Net Income | $2.10B |
| EPS (Basic) | $1.62 |
| EPS (Diluted) | $1.60 |
| Shares Outstanding (Basic) | 1.30B |
| Shares Outstanding (Diluted) | 1.31B |
Key Highlights
- 1Total revenues for Q3 2018 were $5.6 billion, down 14% year-over-year, impacted by lower product sales.
- 2HCV product sales declined significantly (down 59% in Q3 and 61% YTD) due to increased competition, while HIV product sales showed growth (up 12% in Q3 and 10% YTD) driven by new product uptake.
- 3Yescarta, the cell therapy acquired with Kite, generated $75 million in sales in Q3 2018, indicating early commercial traction.
- 4R&D expenses increased by 19% for both Q3 and YTD periods, reflecting investments in pipeline development and integration costs related to the Kite acquisition.
- 5SG&A expenses also increased by 8% in Q3 and 11% YTD, largely due to Kite acquisition-related costs and stock-based compensation.
- 6The company maintained a strong liquidity position with $30.8 billion in cash, cash equivalents, and marketable securities as of September 30, 2018.
- 7Significant debt repayments were made, totaling $1.8 billion in senior unsecured notes and $4.5 billion in term loans, alongside $1.9 billion in share repurchases during the first nine months of 2018.